[STUDY_ID_REMOVED]  Study Protocol and Statistical Analy sis Plan  
 
 Salis bury R01 DA042074  DSM_  Protocol a nd SAP  v051518 
  
Principal Investigat or: Elisabet h B. Salisbury, PhD  
 
Therapeutic Management and Neurobehavioral Outcomes of  Neonatal Abstinence 
Syndrome  
 
Study Protocol and Statistical Analysis Plan v. 051518  
 
Funding: R01 DA042074  (Title of Grant: Stochastic vibrotactile  stimulation: A non -
pharmacological intervention for abstinence and drug withdrawal in newborn infants)  
 
Document Date 12/07/20 
  Page ii 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518  
 GENERAL INFORMATION  
 
 
Name and address of the s ponsor of the study  
National Institutes of Health  
National Institute on Drug A buse (NIDA)  
6001 Executive Boulevard Room 5213, MSC 9561  
Bethesda, MD 20892 -9561 
 
Project officer: Ann Anderson, M .D. 
 
Name and address  of the person s authorized to sign the protocol and 
amendments (by site)  
University of Massachusetts Medical School:  
Elisabeth B Salisbur y, Ph .D. 
Department of Pediatrics  
55 Lake Avenue North S5 -827 
Worcester, MA 016 55 
 
Name and address of study monitor :  
 
Name, title, address and telephone number(s) of the medical expert for the trial : 
Alan Picarillo, M.D.  
Medical Direc tor, NICU  
Henrico D octor’s Hospital  
Sheridan Children’s Services of Virginia  
1602 S kipwith Road  
Richmond, VA 23229  
Alanpicarillo@schr.com  
508-887-5710  
 
Name and title of the investigator(s) and sub -investigator s responsible for t he 
trial with address and phone number(s)    
 
Elisabeth B Salisbury , Ph.D.  
Research Associate Professor  
University of Massachusetts Medical School  
Department of Pediatrics  
55 Lake Avenue North S5 -827 
Worcester, MA 016 55 
 
Elisabeth.Salisbury@umassmed.edu  
508-856-8627  Debra Bogen, M.D.  
Associate Professor  
University of Pittsburgh  
Department of Pediatrics  
3414 Fifth Avenue  
Pittsburgh, PA  15238  
 
Bogendl@upmc.edu  
412-692-6937 
Name and ad dresses of the clin ical laboratories and/or other institutions involved 
in the trial  
1. University of Massachusetts Medical School  
2. University of Pittsburgh  
  Page iii 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518  
Approved modification s not specifically noted in protocol v05.15.18  
    
Date Modification  summa ry Modification summary  Modification  summary  
    
6/8/18  Incorporate home visit s for outcomes 
assessments /alternate co ntact  Add “Ages and Stages ” to 
follow up assessments  Practical e xtension for signed 
cons ent (~30 hrs post birth)   
6/27/19  Clarification  of prisoner ex clusion as 
per Prisoner Certification  OHRP   OHRP acknowledgment of 
Prisoner Cer tification  
(8/1/19)  
3/13/20 As per UMCCTS_IRB Covid -19 study 
restrictions , halt enrollment, all in -
person bedsi de studies, all in -person 
study visi ts; followup  via pho ne; 
adhere to state and site safety 
requirement s.   
8/20/20  State and respective site/ Institutional 
Covid -19 safety  protocol s to resume  
in-person studies ; adhere to state and 
site saf ety protocols ; hybrid  followu p.   
12/7/ 20 Closed enro llment due to 
unanticipated move of P I, required 
study close -out at primary  Instit ution , 
and untimely r eduction in study 
personnel .    
 
 
 
 
  Page iv 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518  
Table  of Contents  
  
1  BACKGROUND  ................................ ................................ ................................ ................................ .. 1 
1.1 TRIAL OBJECTIVES  ................................ ................................ ................................ ..........................  1 
1.1.1  Specific Aims  ................................ ................................ ................................ ...........................  1 
2 SUMMARY OF PROTOCOL  ................................ ................................ ................................ ..............  2 
2.1 BRIEF DESCRIPTION OF THE PROTOCOL (STUDY DESIGN ) ................................ ................................ .. 2 
2.1.1  Investigational Dev ice. Stochastic Vibr otactile Stimulation (SVS)  ................................ ..........  2 
2.1.2  Study Design/Type  ................................ ................................ ................................ ..................  2 
2.1.3  Study Site  ................................ ................................ ................................ ................................  3 
2.1.4  Study Duration  ................................ ................................ ................................ .........................  3 
2.1.5 Randomization ................................ ................................ ................................ .........................  3 
2.2 PRIMARY AND SECONDARY OUTCOMES  ................................ ................................ ............................  4 
 Table 1. Primary and Secondary Endpoints  ................................ ................................ ............  4 
 Table 2. Neurobehavioral Assessment s ................................ ................................ .................  5 
2.3 INCLUSION /EXLCUSION CRITERIA  ................................ ................................ ................................ ..... 6 
2.3.1  Inclusion Criteria  ................................ ................................ ................................ ......................  6 
2.3.2  Exclusion Criteria ................................ ................................ ................................ .....................  6 
2.4 SAMPLE SIZE  AND POWER CA LCULATIONS  ................................ ................................ ........................  6 
2.4.1  Specific Aim 1  ................................ ................................ ................................ ..........................  6 
2.4.2  Specific Aim 2  ................................ ................................ ................................ ..........................  6 
2.4.3  Specific Aim 3  ................................ ................................ ................................ ..........................  7 
3 TRIAL MANAGEMENT  ................................ ................................ ................................ .......................  7 
3.1 LIST OF PARTICIPATING ENROLL ING CLINICS OR DATA COLLECTION CENTERS  ................................ ...... 7 
3.2 PROJECTED TIMETABLE  ................................ ................................ ................................ ...................  8 
 Table 3. Timeline of Benchmarks  ................................ ................................ ............................  8 
3.3 TARGET POPULATI ON DISTRIBUTION  ................................ ................................ ................................  8 
 Table 4. Demographic Characteristics of Regional Maternal Population ................................  8 
4 DATA MANAGEMENT AND STATIS TICAL ANALYSIS  PLAN ................................ ........................  9 
4.1 DATA AC QUISTION AND TRANSMISSION  ................................ ................................ .............................  9 
4.1.1  Specific Aim 1  ................................ ................................ ................................ ..........................  9 
4.1.2  Specific Aim 2  ................................ ................................ ................................ ........................  10 
4.1.3  Specif ic Aim 3  ................................ ................................ ................................ ........................  11 
4.2 DATA ENTRY METHODS  ................................ ................................ ................................ .................  12 
4.3 DATA ANALYSIS PLAN  ................................ ................................ ................................ ....................  12 
4.3.1  Overview  ................................ ................................ ................................ ................................  12 
4.3.2  Specific Aim 1  ................................ ................................ ................................ ........................  13 
4.3.3  Specific Aim 2  ................................ ................................ ................................ ........................  13 
4.3.4  Specific Aim 3  ................................ ................................ ................................ ........................  14 
5 QUALITY ASSURANC E ................................ ................................ ................................ ...................  14 
5.1 PROCEDURES IN PLACE TO ENSURE THE VALIDITY AND INTEGRITY OF T HE DATA  ...............................  14 
5.2 PROCEDURES TO GU ARANTEE THE ACCURACY AND COMPLETENESS OF THE DATA , DURING DATA 
 COLLECTION , ENTRY , TRANSMISSION AND ANALYSIS  ................................ ................................ ....... 15 
5.3 MONITORING MISSING DATA  ................................ ................................ ................................ ...........  15 
  
6 REGULATO RY ISSUES  ................................ ................................ ................................ ...................  16 
6.1 REPORTING SERIOUS ADVERSE EVENTS (SAE) AND SUSPECTED ADVERSE REACTI ONS (SAR) .............  16 
6.1.1 Definitions  ................................ ................................ ................................ ..............................  16 
6.1.2  Adverse Event Follow -Up ................................ ................................ ................................ ...... 17 
  Page v 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 6.2 REPORTING OF IRB ACTIONS TO NIDA  ................................ ................................ .............................  17 
 
6.3 REPORTING OF CHANGES O R AMMENDMENTS TO T HE PROTOCOL  ................................ ....................  17 
6.4 TRIAL STOPPING RULES  ................................ ................................ ................................ .................  17 
6.5 DISCLOSURE OF ANY CONFL ICT OF INTEREST (COI) IN THE DSMP ................................ ......................  18 
7 TRIAL SAFETY  ................................ ................................ ................................ ................................ . 18 
7.1 POTENTIAL RISKS AND BENEFITS FOR PARTICIPANTS  ................................ ................................ ....... 18 
7.1.1  Potential Risks  ................................ ................................ ................................ .......................  18 
7.1.2  Potential Benefits  ................................ ................................ ................................ ..................  18 
7.2 COLLECTION AND REPORT ING OF AES AND SAES  ................................ ................................ .............  19 
7.3 MANAGEMENT OF SAES OR OTHER STUDY RISKS  ................................ ................................ .............  19 
 
8 TRIAL EFFICACY  ................................ ................................ ................................ .............................  19 
8.1 PLANS F OR INTERIM ANALYS IS OF EFFICACY DATA  ................................ ................................ ..........  19 
9 DSM PLAN ADMINISTRATION  ................................ ................................ ................................ ....... 20 
9.1 RESPONSIBILITY FOR DATA AND SAFETY MONITORING PLAN  ................................ .............................  20 
9.2 FREQUENCY OF DSM B REVIEWS  ................................ ................................ ................................ ..... 20 
9.3 CONTENT OF THE DSMB REPORT ................................ ................................ ................................ .... 20 
9.4 DSM BOARD PLAN  ................................ ................................ ................................ .........................  21 
 
 
 
 
 
  Page vi 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 List of Abbreviation s 
 
 
COI  Confl ict of Interest  
 
DSMB   Data Safety Monitoring Board  
 
DSM P  Data Safety Monitoring  Plan 
 
EMSM  External Medical Safety Monitor  
 
IRB  Institutional  Review Board  
 
NAS   Neonata l Abstinence Syndrome  
 
PI  Principal Investigator  
 
REDCap  Research Ele ctronic Data C apture  
 
SAE  Serious Adverse Events  
 
SAR  Suspected Adverse Reactions  
 
SCC   Standard Clinical Care  
 
SVS  Stochastic Vibrotacti le Sti mulation  
 
 
 
 Salis bury R01 DA042074  DSM_  Protocol a nd SAP  v051518 
 1 BACKGROUND  
 
Neonatal Abstine nce Syndrome (NAS) refers to a variety of withdrawal symptoms, 
particu larly prevalen t in newborns wit h opioid exposure. Clinically significant 
neurobehavioral symptoms include pathophysiological cardio -respirat ory in stabilities,  
gastrointestinal dysfunctio n, hypersensitivity, and sleep disruption . There is a critical 
need to  develop non -pharmacological in terventions for managing withdrawal in 
newborns to reduce withdrawal symptoms, facilitate weaning, decrease 
pharmac otherapy, an d provide additional interve ntion for infants in whom 
pharmacological treatment is insufficient. G rowing researc h suggests the im portance of 
sensory tactile stimulation for promoting physiological maturation, brain development, 
and stabil ity of  function, a nd for improving behaviors i mplicated in intrauterine drug 
exposure. Evidence supports that low -level, stochasti c (random) stimul ation can 
promote stability in destabilized biological systems, including improved transduction of 
cutaneous mechan oreceptors i n animals, sensory perceptio n in adults, and improved 
cardio -respiratory function in premature inf ants. Our rece nt pilot data sug gests that 
acute presentation of low -level stochastic vibratory stimulation (SVS) delivered through 
a uniquel y-cons tructed crib  mattress improves physiolog ical function in drug -
withdrawing infants. We hypothesize that stochas tic resonance may affect 
somato sensory and vestibular systems by facilitating more accurate detection of 
sensory inputs ( e.g., touch, audito ry) an d increase n eural stability. For example , SVS 
may stimulate pressure receptors to improve vagal tone and cardi ac activity, a nd 
impinge upon r espiratory oscillators to enhance respiratory function . The main objective 
of this proposal is to test whethe r earl y interventi on (initiated within 24 hour s post birth) 
and daily administration of SVS reduces withdrawal and i mproves neurob ehavioral 
outcome s. 
 
1.1 Trial Objectives  
This study  investigates Stochastic Vibro tactile Stimulation (SVS) co mplementary to 
stand ard of  care for treating NAS. Using a speciall y-constructed crib mattress we will 
determine if SVS reduces symptoms and duration o f NAS and improve s long term 
outcomes in intrauterine opioid -exposed newborns. Findings from this study will 
elucidate whether  SVS h as potential  as a therapeutic treatment for drug -exposed 
newborns to reduce symptomatology, facilitate weaning  and minimize hospitalization, 
with implications f or better regulation of systems and  improved developmental 
outcomes.  
 
 1.1.1. Specific Aim s. The three areas  to be investigated in this project are:  
 Specific Aim 1.  Determine the efficacy of SVS as a non -pharmacological  
therapy compleme ntary to standard clinical care (SCC) for reducing severity and 
duration of opioid withdrawal in newborns com pared to SCC alone . Quantify 
clinical variable s: NAS severity /administration  of treatment , treatment days, days in 
hospital, veloc ity of weight gain, cumulative  morphine dose, and longitudinal 
assessment of movement activity.  
  Page 2 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518  Specific Aim 2. Examine physi ologic al responses  to SVS compared to SCC at 
two stages  of withdrawal severity.  Measure cardio -respiratory stability, temperature 
regulation, and m ovement activity . 
 Specific Aim 3. Compare neurobehavioral outcomes in fetal drug -exposed 
infants between inf ants w ho received SVS and those who received S CC. Examine 
longitudinal outcomes assessment s at 1 month, 6 -months and 1 year to tes t whether 
early i ntervention with SVS compared to SCC  improves physical, social, emotional and 
cognitive development.   
 
2 SUMMA RY OF THE PROTOCOL  
 
2.1 Brief Description of the P rotocol (Study Design)  
The proposed experiments aim to examine whether SVS, using a spec ially-designe d 
crib mattress, has potential as a complementary treatment of NAS . We will determine if 
SVS reduces N AS seve rity (administrati on of treatment/treatmen t days), cumulative 
morphine dose  and days in hospital, reduces  specific physiological m arkers of 
withdra wal (excessive movement and cardio-respirat ory instabilities ), and improves 
neurodevelopment outcomes in the first year of life .  
NOTE:   All changes to the  protocol must be approved by NIDA prior to implementation.  
 
2.1.1. Investigational Device . Stochasti c Vibrotactile Stimulation (SVS) . The 
infant’s crib mattress will be replaced with a specially constructed ma ttress  (non-
commer cially available) to provide  gentle vibrations and sounds during mattress 
stimulations. The mattress is embedded  with mechanical actuators that provide whole -
body SVS (30 -60Hz; ~ 10-12µm RMS).  Co Fab Design , LLC  will construct the 
mattress es and  drivers as per the design documents fur nished under Confidentiality 
Disclosure Agreement (CDA; University of Massachusetts Medical School/Wy ss 
Institute -Harvard University patent: PCT/US2015/021999 ) for research purposes only as 
per the licensed mat tress assembly and  electrical assembly and ver ification 
documentation ; device components may be modified with improved technologie s that 
provide eq uivalent mattress output to help ensure consistency of mattress integrity over 
time. Engineers from the Wyss Instit ute and the University  of Pittsburgh wil l provide 
assistance in the build to e nsure it performs as per the original patent d ocumentation .  
2.1.2. Study Design/Type . This study is a randomized, placebo -controlled, 
parallel group clinical trial. Eligib le pat ients will b e randomized into one of two  groups in 
a 1:1 ratio, matched for ge nder, to either (1) SVS or (2) SCC:  
 
1) SVS. Experimental Inter vention: Newborn infants at -risk for NAS due to opioid 
exposure in utero  randomized to this arm will receive daily intervals of  continuous SVS 
(ON) and no SVS (OFF) throughout hospitalization, starting within 30-hrs post birth. An 
automate d control box wil l be set to deliver continuous alternating 3 -hr cycles of 
ON/OFF intervals. A stimulation period will always be fol lowed by an interval of no 
stimulation; in any 24 -hr period an infant will not  receive more than a total of 12 hrs of 
stimul ation (should the  infant remain in the crib throughout an entire 24 hr period). 
Notably, infan ts are not always in their crib  and it  is not feas ible to provide round -the-
clock research staffing to monitor when the infant is in or out of the crib (e.g., bei ng held 
  Page 3 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 by caregi ver, fed, in motorized bedside glider – all part of the standard of care). The pre -
programmed 3 -hr duty cycle , 24/7 , affords op portunity to capture periods  when the 
infant is in the crib, and a lso conforms to routine timing of medication. Periods of 
stimul ation will be complementary to standard of clinical care (e.g., clinically -determined 
pharmacological managem ent; r outine holdi ng by caregiver or hospital -issued 
motorized glider; breast and/or  bottle feed). A bedside log will indicate per iods the infant 
is in the crib, being held, or placed in hospital -issued gliders/motorized seats. Infants will 
be scored for s everit y of withdra wal using standardized, modi fied Finnegan scoring 
system by clinic al-care nurses per routine clinical care throu ghout hospitaliza tion, and 
may receive pharmacological treatment as per standard care determined by the 
medical -care team at t he res pective inst itution.  
 
2) SCC . No Interve ntion: Standard of Clinical Care (SCC) . Newborn infants at -
risk for NAS due to opioi d exposure in ute ro randomized to this arm will be enrolled 
within 30-hours post birth and receive standard of care (e.g., cli nicall y-determined  
pharmacological management;  routine holding by caregiver or hospi tal-issued 
motorized glider; breast and/or bot tle feed). Infant s will be issued a hospital crib 
mattress.  A bedside log will indicate periods the infant is in the crib, bei ng hel d, or 
placed  in hospital -issued gliders/ motorized seats.  Infants will be score d for severity of 
withdrawal using standardize d, modified Finne gan scoring system by clinical care 
nurses per routine clinical care throughout hospitalization , and may receive 
pharmacologica l treatment as per standard care determined by the medical -care te am 
at the respective institution.  
 2.1.3. Stud y Site .  Studies will be conducted at the UMass Memorial Healthcare 
Neonatal Intensive Care Unit (NICU), Continuing Care Nurse ry (CC N), and Newb orn 
Nursery (NN) – referred to as UMass - and at the Magee -Women’s  NICU and Well -
Baby Nurser y, and Mercy Hospita l, of the Univers ity of Pittsburgh Medical Center – 
referred to as UPitt - where infants receive round -the-clock medical care.  Studi es for 
Aim 1  and Aim 2 will be performed  at the infant's hospital bedside, outcome 
assessments  for Aim 3 will be performed a t respective hosp ital inpatient (if infant still 
hospitalized) and outpatient facilities .  
 
  2.1.4. Study Duration .  Subjects  will participate in the stud y throughout thei r 
hospitalization , beginning within 30 hours post birth,  and will be followed for up to 14 
months  post post -hospital discharge via medical records, telephone interviews, and 
return visits for outcome assessment s. 
 
  2.1.5. Rando mization . Random allocation of subject  to treatment  (SVS or SCC)  
will involve a permute d block design with rando m block sizes to assure equal treatment 
assignment for both treatments. We will stratify the randomization pr ocess by clinical  
site to force  a balance betw een treatment  groups and gender within each site. The 
random treatment assig nments will be generated in SAS and upload ed into the IVRS 
system. The randomization process will verify patient eligibility before issuing treatment 
assignm ent. Treatme nt assignme nts will be in th e form of mattress  assignment tracked 
by the IVRS system ba sed on admission and disc harge information  entered into 
REDCap  (See 4.2 below ).  The IVRS system can be accessed by certified study staff 
  Page 4 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 either throug h a te lephone call  or over th e internet to a s ecure web site. The treatment 
assignments are recorded auto matically in the REDCap s ystem through an interface 
between the two systems and cannot be modified once imported from the IVRS system. 
The randomizatio ns are  monitored a nd verified  by study staff o n a routine basis. The 
IVRS also will monitor mattress  availability and will notify study staff if a mattress  of 
each type is not available for a randomization.  (Maternal exposure will be stratified in 
the anal ysis).  
 
2.2 Primary  and Secondary  Outcome Measures   
 
Table 1 : Primary and Secondary Study E ndpoints.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Aim 1  
Primary  
Clinical 
Outcomes  Aim 1 
 Longitudi nal 
Physiological 
Outcomes  Aim 2 
Acute  
Physiolo gical  Outcomes  
(UMass only)  Aim 3  
1-Year  Follow -Up 
Assessmen t 
Outc omes 
Outcom e 
Variables  NAS Severity 
Scores (trajectory: 
daily averages and 
max scores)  
 
Weight Gain/ Head 
Circumference 
(trajectory: daily 
measures)  
 
Pharmacotherapy: 
admin , type, dose 
(cumulati ve 
dose/normalized 
for body weight)  
 
Hospital Duration:  
Day o f life infan t is 
discha rged from 
hospita l (length of 
stay)  Movement Activity:  
12 and 24 hr 
assessments  
actigraphy  (averages : 
trajectory; fre quency; 
index of sleep ) 
 
 Movement Activity 
(frequency  and duration; 
histograms): Index of 
irritability and s leep 
disruption/fr agmentation   
 
Cardio -Respira tory control 
(mean/histograms : 
respiratory rate, frequency 
distribution; heart rate,  
frequency distri bution ) 
 
Other NAS 
Symptomatology: 
Temperature/Oxygena tion 
(mean)  Environmental and 
Family Function (1 -6-
12 m o) 
 
Functional Sta tus  
(1-6-12 mo)  
 
Neurodevel opment  
(1-6-12 mo)  
 
Behavioral and 
Emotional Status (6 
and 12 mo)  
 
Parent Intellect ual 
Ability  
(1 x assessment)  
 
Brief Infant Sleep 
Questionnaire (1 -6-
12mos)  
  Page 5 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 Table 2: Neurobehav ioral Asses sments . 
 
Note: 1mo, 6mo, and 12mo time points are approximate testing periods. Assessments will primarily b e 
admi nistered by Outcomes Sp ecialist in the o utpatient clinic/office or at home visits, except in 
some instances:  
3 1) BSI and McFa d questionnaires may be administered in hospital by resear ch study staff to obtain 
baseline assessment while the infant and/or  mom a re still in hospital (m ay be performed b y 
Outcomes Specialist at 1mo outpatient visit if unable to administer while in hospi tal).  
4 2) GOSE -E Peds and BISQ will not be performed at th e 1-month time point if the infant is  
hospitalized at timeframe of t esting  period ; we anticipate all infants will be discharged before the 
6mos assessments.  
 3) If study staff are unable to do asse ssments in person  (i.e., study staff unable to schedule 
assessment when subject is in -patient, at outpatient clinic/office or home v isit) the fo llowing 
questionnaires may b e performed by research study staff over the phone: GOS -E-PEDI, PedsQL, 
PEDI, BISQ, Bayley S&E, BSI, McFad.  The Bayley iii measures of neurod evelopment and WASI 
cannot be performed over the phone.  
4) *WASI may  be ad ministered a nytime thro ughout the study period by Outcomes  Specialist.                   Task (time )  
Testing Age Description a nd respondent [Child (C) or parent (P)]  Key Variables  
Functional Status  of Infant  
GOS -E Peds[59] (10’) 
1mo, 6mo, and 12mo  The 8 GOS -E Peds cate gories track recovery of function between groups. 
This version includes semi -structu red interv iew que stions relevant to infants.  
Administered by Outcomes Specialist.  (C, P)  (Upload: Pcori -GOS).  Category score  
(1-8) 
Pediatric Q uality of L ife[58] (5’) 
6mo and 12mo  The PedsQL  Parent Report for Infants is availabl e for age ranges from 1 to 12 
months.  Scales assess physical function, physical symptoms, emotional 
function, social function , and cognitive fu nction.  Administered by Outc omes 
Specialist or Research Study Staff.  (P) (Upload: Peds QL)  Total score ; 
Subscale  scores  
Neurodev elopment  and Sleep Status of Infant  
Bayley Scales of Infant & 
Toddler 3rd Ed.[60]  (30’) 
6mo and 12mo  The Bayley iii m easures neurodevelopment to 3 yrs. Pr ovides measures o f 
cognitive function: visual preference, attention, memory, sensorimotor, 
exploration, manipulation, concept format ion. Fine an d gross mot or 
development ar e also assessed.  Administered by Outcomes Specialist.  (C) 
(Upload: Bayley Record Fo rm) Cognitive & M otor 
Scores; Subtest 
scaled scores  
Pediatric Evaluation of 
Disability Inventory[61]  (10’) 
6mo and 12 mo  The PEDI Mobility domain pr ovides a standardized assessment of mobility 
skills appropriate  for children up t o the age o f 4 years.  Admini stered by 
Outcomes Specialist or Research Study Staff.   (C) (Upload: Pedi Self Care 
and Mobility)  Mobility Score  
 
Brief Infant Sleep 
Questionnaire (Sadeh, 2004)  
1mo, 6mo, 12mo  The BISQ is a modified questionna ire th at provides a general a ssessment of 
infant sleep behaviors. Administered by Outcomes Specialist or Research 
Study Staff.   (P) (Upload modifie d BISQ)  General Sleep 
Assessments  
Behavior & Emotional Status  of Infant  
Bayley Social and Emotional 
Scale[60] (10’)   
6mo and 12 mo The Bayley S&E  measures emotional adjustment of infants and toddlers. 
Administered by Outcomes Specialist*.  (P) (Upload Bay ley So cial and 
Emotional Scal e) Composite Scor e 
Parent Intellectual Ability  and Psychological Status  
Wechsler Abbreviated Scale 
of Intelligence[57]  
(20’)  
*1mo The WASI ii  is a s hort a nd reliable measure of intelligence in c linical, psycho -
educational, and research settings and is individually administered.   2 
subtests will  be used to generate a FSIQ: Vocabulary requires individual to 
define words of increasing difficulty; Block D esign assesses abi lity to 
construct two dimens ional designs from multicolored blocks.  Administered by 
Outcomes Specialist.   (P) (Upload: W ASI-II) 2-Factor IQ  
Brief Symptom Inventory -18 
1mo (baseline) , 6mo, 12mo  The BSI provides a valid assessment of adul t psyc hiatric stat us, includi ng the  
domains of  depression, anxiety, and somatization. Administered by Outcomes 
Specialist or Resea rch Study Staff.   (P) (Upload BSI)  GSI; subtest T -
scores  
Environment and Family Function  of Parent  
General Functioning Scale  [66]  
(5’)  
1mo (baseline), 6mo,  12 mo The McFad is a  subscal e from McMaster Fa mily Assess ment Device 
(FAD) .12-item scale is an overall measure of family functioning and has been 
shown to int eract with illnes s severity and pediatric outcome studies using the 
FAD.  Completed at study entry, 6mo, and 12  month evaluati on to track 
change s in family  function over ti me.  Administered by Outcomes Specialist or 
Research Study Staff.   (P) (Upload: Adap t McFad v1.0)  Total score  
  Page 6 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 2.3  Inclusion/Exclusion Criteria    
A total of 230 full-term ( >37wks gestational age) newborn infants exposed to opioids in 
utero  will be studied over the five -year f unding perio d: 100 at U Mass and 130 at U Pitt.  
 
  2.3.1. Inclusion  Criteria . Infant inclusion criteria include documented op ioid drug 
exposur e (i.e., positive toxicology screen; exposure questionnaire and medical record 
history) and comprise the gene ral po pulation (Wo rcester, MA  and Pittsburgh, PA 
demographics) wit hout restriction in regard to gender, race or socioeconomic stat us. 
Infants may a lso have additional prenatal poly -drug exposure (e.g., benzodiazepines, 
barbiturates, amphetamines, cannabino ids, a lcohol, nico tine and/or  caffeine).  Inclu sion 
of pregnant women is for the sole purpose of obtaining consent to study the inf ant post -
delivery , and to review infant and maternal  medical records.  Pregnant women are 
included because we will be recruitin g preg nant women w ho are at r isk for deliverin g 
infants with NAS due to drug exposure in utero. Prenatal consents are needed to he lp 
expedite feasi bility of study of infants soon after delivery. Infa nts will not be studied in 
utero, but will only be studie d afte r delivery.  
 
  2.3.2. Exclusion  Criteri a. Subjects with  clinically significant  fetal anomaly, 
congenital abnormality, adver se pregnancy outc ome, hydrocephalus or intraventricular 
hemorrhage >g rade 2, seizure disorder not related to drug withdrawal, clinic ally 
signifi cant cardia c shunt, anemia ( hemoglobin<8g/dL), requires mechanical respiratory 
support  or is being treated for MRSA or infection at the time of the study will be 
excluded , or other medical conditio n aside from NAS will be excluded. Inform ed con sent 
will be  obtained from parent(s) or legal guardian of all participants.  
 
2.4 Sample Size and Power Calculations  
For all  Aims there is su fficient sample size to detect clinically meaningful differences 
with 90% power , described below:  
 
  2.4.1. Specifi c Aim 1 . We use the Finnegan NAS score a s the primary outcome 
for this aim. From Nayeri et al.  [70] and our own pilot data, the Finnegan NAS score in 
opioid -exposed infants had a SD of 2.0 -2.5. Assuming a stan dard t -test with a two -sided 
alpha level of 0.0 5 for the un adjusted comparison of the F innegan scores at a particular 
time point with the more conservative standard deviat ion (SD.=2.5), th e sample size of 
115/group can detect a difference of 1.1 with 90% p ower. Taking into account the 
repeated me asures  of the Finn egan NAS score, assuming int ra-infant correlations of 
0.5-0.7, we will have 90% power to detect a difference of 0.80-0.95 in a mi xed effects 
model for the overall (i.e., across time) treatment grou p coefficient. With a mixed effects 
model , we w ill also add  covariates as described abo ve to determine an adjusted 
treatment effect. We expect that this model may have eve n more power than  described 
here due to the partitioning of the overall variance amon g the covariates. Because 
infants are hos pitalized and u nder observation until release,  we expect only minimal 
attrition and loss of information.  
 
  2.4.2. Specific Aim 2.  We use Movement as primary outcome for this aim . 
Based on our preliminary data in 26  NAS infants (OFF: mean movement 40% of 
conditi on time, SD= 10%; ON: mean movement 26% of condition time, SD=9%) and 
  Page 7 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 assuming a two -sided paired t -test at alpha=0.05 for th e unadjusted trea tment effect, we 
estimate 25 infants per group will give us 90% powe r to detect a reduction of 7% in 
movement  betwe en the two t reatment groups (a relative reduction of about 20% from 
40% in OFF to 33% in ON) with a conservative SD of 10% ( from the pilot st udy).   
 
  2.4.3. Specific Aim 3.   We use Bayley -III as primary outc ome for this aim. We 
anticipate an attrit ion ra te of ~40% i n the 1 -year follow -up asses sments.  Assuming a 
sample size of 60 children/group at 1 year with a two -sided stan dard t -test at 
alpha=0.05 and a SD of 14 for the Bayley -III cognitive composite scale , [71] we will 
have 90% power to detect a  difference of 8.5  (or about a 12% difference)  between the 
two groups at 1 year of age. The other Bayley scales have similar SDs, so the results 
will be similar. For a longitudinal analysis of the Bayley -III cogniti ve composite scale 
over the follow -up vis its (1 , 3, and 12 months of age), we will use a mixed effects model 
as above with months of age as the time metric in the model. A ssuming the same 
sample size with intra -child correlations of 0.5 -0.7 for a mixed eff ects model with a two -
sided test for the treatm ent group co efficient at alpha=0.05, we will have 90% power to 
detect a treatment effect of 6.8 -7.4 (depending on the correl ation) using the treatment 
group coefficient. We can also add covariates to this mode l to estimate an adjusted 
treatment effec t.  
 
 Each child w ill be classified as impaire d or not based on the results of the battery of 
tests given over one year.[69] Assum ing a worse -case scenario (in terms of SD of a 
proportion) of 50% impairment in the S CC group, with 60 children/group we will have 
90% power to detect an unadjusted absolut e improvement of 28% (50% vs. 78%) or a 
relative improvement of 56% in the SVS group  with a z -test wi th a two -sided alpha 
=0.05. For an adjusted estimate of the improvem ent in percent impairment at one year, 
we will use a logist ic model with other covariat es added. For a longitudinal assessment 
of impairment, we will use a GEE longitudina l logistic model with the same approach for 
model building as above.  
 
5 TRIAL MANAGEME NT 
 
3.1.  List of Participating Enrolling  Clini cs or Data C ollection Centers  
1. Univers ity of Massachusetts Medical School:  
 1) University of Massachusetts Memorial Hospit al: 
  a) Faculty and Resident Outpatient Obstetrical Clinics  
  b) NICU Prenatal -NAS C linic 
  c) Newborn Nursery  
  d) NICU/CCN  
 2) Un iversity of Massachusetts Children’s Cen ter 
a) Pediatric Unit/Outpatient Outcomes Assessment Facilities  
2. University of Pit tsburgh  
 1) Unive rsity of Pittsburgh Medical Cente r and Magee Women’s Hospital of 
UPM C: 
  a) Outpatient Obstetrical Clinics  
  b) Pre gnancy Recov ery Center  
  Page 8 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518   c) Newborn Nurs ery/Well -Baby Nursery  
  d) NICU  
      2) Mercy  Hospital at UPMC  
  a) NICU  
   
3.2.  Projected Timetabl e 
Table 3 . Timeline of Benchmarks.  
 
 
3.3.  Target Population D istribu tion (e.g, W omen, Minorities, etc)  
The p roposed study requires involvement of huma n subjects, specifically infants, for the 
purpose of invest igating the therapeutic efficacy of SVS for reducing symptomatology 
and pathophysiological instabilities ass ociated  with neonat al abstinence and drug 
withd rawal, and for improving neurobehavioral o utcomes. We will attempt to recruit 
subjec ts who are male o r female, and from all ethnic backgrounds. We will not exclude 
subjects for any reason based on race, sex, r eligion , ethnic bac kground or national 
origin. The racial mix of the Worcester, MA and Pi ttsburgh, PA regional areas are 
identified  in Table 4. We e xpect to be able to do the same for the proposed study with 
the caveat that the proportions of minorities wi ll reflect the appr oximate subpopulation 
propor tions of patients admitted to UMass and UP itt with intrauterine opioid exposure.  
 Benchmarks  Year 1  Year 2  Year 3  Year 4  Year 5  
Estimated Enrolled Subjects  UMass /UPitt (230 
total: 100UMass; 130UPitt)  25/22 25/36  25/36  25/36    
Data Safety and Monitoring Board : Bi-annual 
reports  X X X X X  
Monthly Mee tings with Research Personnel  X X X X X 
Investigator Site Visits  X X X X X 
Aim 1 and Aim 2: Newborn In -hosp ital S tudies:        
Demographic/Medical Histo ries; Mattress 
SVS/SSC (daily); Actigraph (daily) ; 2 full 
physiology studies (10 -15/yr) X  X X X X 
Aim 3: Outcomes Studies  X X X X X 
Telephone Interviews; Outpatient Outcomes (3 
sessions)            
End of Ye ar Rep ort:      
Deliver up -to-date data base  (demographic, 
medical, actigraph, outcomes  testing); Deliver 
copy of study logs; Sum mary Report by site PIs X X X X X 
Investigator s Present  Preliminary Data at 
Scientific Conference /s     X X X 
Data Collecti on Comp lete       Newborn  
Studies  Outcomes 
Testing 
Final d ata sets delivered to UMass 
biostatistician s; PIs submit  final site repo rts: study 
enroll ment and attrition for each arm of study; 
Final Analysis and Writing          X  
  Page 9 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 Table 4.  Demograph ic Characteristics of Regional Maternal Population.  
 
 
 
 
 
 
 
 
4. DATA MANAGEMENT A ND STATISTICAL ANALYSIS  PLAN  
 
4.1.  Data Acquisit ion and Transmission  
4.1.1. Specific Aim 1 . Determine the efficacy of SVS as a non-pharmacological 
therapy  complementary to standard clinical care (SCC) for reducing  severity and 
duration of  opioid withdrawa l in newborns compared to SCC alone - Standard 
Measurements and Recordings.   
 
1) Medical history.  Prenatal exposure (e.g., pre scribe d maintenance therapy, 
prescription drugs and substance use during pregnancy inclu ding toxicology screens 
indicating drugs o f exposure) and demographic data (gender, race, gestational age, 
birth weight, birth head circumference, delivery mode, anesth esia a t delivery) will be 
obtained from infant and mother via questionnaire and medical records to help identify 
variables that ma y be associated with withdrawal and outcome measures.  Subject’s 
medical records will be reviewed and additional history will b e obtained from 
parent/guardi an, including review of child’s mother medical records if t he child was 
delivered at  UMass. We reques t protected health information from general medical 
records and review of statutorily protected records at this institution to : 1) Obtain 
toxicology report s indicating drugs of exposure and other relevant records p ertaining to 
NAS; 2) Make  sure the child m eets our inclusion criteria. An example would be to 
confirm that a child has not been diagnosed with a disorder that may cause  cardi o-
respiratory instabili ty, such as intraventricular -hemorrhage greater than grade 2; 3) 
Obtain information about factors tha t may affect responses we observe during 
stimulation. For example, pregnancy or delivery complications, exposure to drugs in 
utero, or prescribed medicatio ns that may alter breathing and heart rhythms. We 
request t o review both the child’s  and mother’s med ical records for information from 
cardiac studies, nursing and respiratory therapy notes, clinical monitor information, 
discha rge su mmaries, EEG/EMG studie s, laboratory results, operative procedures, 
conclusive pat hologies, clinical proble m list, and pulmo nary, radiology and rehabilitation 
information. There will be 1 -year follow up on study infants through medical record and 
telephone  interview. Data will b e entered by a research investigator via secure 
password pr otected computer into RED Cap database (RED Cap Consortium, Vanderbilt 
University) – see 4.2 below Data Entry Methods . 
 
  2) Chart Review/Bedside Log . NAS severity scores . The infant’s clinical -care 
nurses at each site are routinely trained on the NAS assess ment tool (modified Maternal Race  UMass (%)  UPitt (%)  
African American  5.3 19.7 
Hispanic or Latino  10.5 1.1 
Asian  4.7 2.4 
Caucasian  78.8 75.2 
Native American  0.4 0 
Two or More Races  2 1.6 
  Page 10 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 Finne gan Scale)[63] as part of clinical education; this helps ensure reliability of scores. 
Nurses score the infants’ withdrawal  severity ~every 3 -4 hrs to assess changes in 
central, auto nomic, vasomotor and gast rointestinal func tion. Daily NAS scores, weight 
(gain/loss; trajectory), head circumference, routine feed type (formula or breast milk), 
pharma cologi cal management (medicat ion, dose normalized for body weight), and birth 
date and d ate of hospital will be obtained  from medi cal and/or nursing  chart review. A 
computerized and/or paper log (de-identified, subject id only)  will be kept by the infant’s  
bedsi de to record when the i nfant is in the crib, and nursing/parent interventions (e.g ., 
feeds, diapering, care giver cuddling, a nd placement in motorized swings). This provides 
some indication of the infant’s routine clinical care since investigators can not be  at the 
bedside 24/7. A  separate log kept by investigators will be used to record pre-
programme d time onset  and offset of SV S (i.e., to verify d aily automated SVS coinciding 
with log indicating when infant is in the crib to receive the intervention ). Data will be 
entered by a re search investigator  via secure password protected computer into 
REDCap database . 
 
  3) Movement Activ ity. Movement periods will be assessed via actigraphy, a 
simple non -invasive measurement using a wireless, lightweight sensor worn a round the 
infant’s limb  (Respironics®). The sensor is ~1.5”x1” and held in place w ith a soft foam 
tapeless wrap (Posey®). Ac tigraph sensors applied to the infant’s limb will continuously 
record the frequency of movements throughout the duration of th e infant’s 
hospitalization, s tarting within 24 -48 hrs post birth. This will allow measur ement of 
frequency of leg  movements (index  of irritability, sleep fragmentation, wake and 
quiescence (index sleep) throughout hospitalization).[46, 47] Data will be r ecorded in 1 -
min epochs to evaluate for movement frequency (index of activity) and quiescence over 
12h and 24h intervals  and/or d uring periods when i nfants are documented i n the crib 
(mattress on or off) . Digitized signals will be stored on electronic data  base. Data will be 
analyzed via computerized programs , stored in excel spreadsheets, and entered by a 
research investigator via sec ure passwor d protected computer into RED Cap database.  
 
  4.1.2. Specific Aim 2 . Examine physiologic al responses to SVS compa red to 
SCC at two  stages of withdrawal severity – Standard Measurements and Recording.   
 
  Changes and relationships among physiolog ical signal s will be quantified in a 
sub-population of study infants at UMass. For each session, ph ysiological signals will be 
recorded conti nuously for ~6-8 hrs  using proprietary acquisition system . Respiratory 
inductance plethysmography  will be used to me asure infa nt’s breathing (Somonstar®); 
infant’s abdominal muscle movement will provide detection o f interbreath intervals 
(index of respirat ory stability) and respiratory rate. Electrodes over the skin surface of 
the chest will be used to record electrocar diographic  activity (ECG; Embla®) to al low for 
detection of cardiac R -R intervals (index of interb eat variance and heart ra te). A probe 
attached to the infant’s foot will measure arterial -blood oxygen concentration (Masimo®). 
Quality of the plethysmographi c activity  chara cterized in the pulse s ignal will also allow 
for identification of movement period  duration . Movement frequ ency will be asse ssed 
with actigraphy using a wireless sensor worn around the infant’s limb (Respironics®). 
Infant axillary temperatu re will be  measu red continuously with a  sensor placed under 
  Page 11 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 the infant’s armpit or back (Physitemp®). Environmental changes  in sound intensi ty and 
light level will be measured with meters placed in the crib near the infant’s head 
(Extech®). Overt behaviora l data wil l be recorded using sound -video camera with a 
wide-angled lens.  
 
  Physiological data w ill be digitally recorded  (~50-1kHz sample s per channel) 
using an acquisition system that directly obtains signals from the NICU bedside monitor 
(Philips®; Wy ss Institu te, Ha rvard University) or vi a an independent system (Embla®). 
These systems enable full y synchronized recordings  of physiological  signals, 
audiometry, photometry and digital video images. Comments regarding routine nursing 
assessments and other relevant i nforma tion (e.g. feeding, pha rmacological dosing) will 
be typed and time stamped along w ith the physiological dat a stream. Acitgra ph activity 
will be digitally recorded independent of the full -acquisition system. All signals, video 
images and ger mane data (e.g., medical histories of i nfant and mother, NAS severity 
assessments) will be stored on electronic data base. Investigators wil l also manually 
record relevant study information (timing and mode of experimental conditions, nursing 
assessments, feeds, med icatio ns etc) stored in the e lectronic data base.  
 
  Data is analyzed via proprietary software and via advanced computational 
models of analysis developed for this study. Final outputs will be stored on password 
protected computers in excel data  bases and  will be entered by a researc h investigator 
via secure password protected computer into REDCap database.  
 
  4.1.3. Specific Aim 3 . Compare neurobehavioral outcomes in in the first year of 
life between infants who received SVS and those who receiv ed SCC – Standar d 
Measurements and Reco rdings.  
 
  1) Follow -up Chart  Review and Telephone Intervie w. For a period of up to 14 
months  post ho spital discharge we will review hospital medical records for inpatient and 
outpatient visits (if the infant is treat ed at UMas s or UPitt) for information r elated to 
outcomes for neonatal drug exposure. We will also  follow -up for 14 months  post-
hospital dis charge with phone -call questionnaires (approx. every other month) to help 
identify outcomes associated with infants requiring prolon ged pharmacotherapy and  
those discharged without medication, and to determine if t here are differences in 
outcomes in infant s treated with SVS vs SSC. Data will be entered by a research 
investigator via secure password protected computer in to REDCap databa se. 
 
 2)Anthropomorphic  Examination . Infant weight, height, and head 
circumference  are measured in the deli very room and rec orded in medical record  
throughout hospitalization . Data will be entered by a research investigator via secure 
password protec ted co mputer into REDCap data base . 
 
 3) Neurobehavioral Assessments . Outpatient assessme nts will be conducted 
at 1 month, 6 months  and 1 2 months (see Table 2). Data will be entered by a research 
investigator via secure password protected computer into REDC ap dat abase. 
 
  Page 12 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 4.2 Data Entry Methods  
The data for this study will be recorded in a REDCa p database (REDCap Consor tium, 
Vanderbilt Univer sity) in the secure regulated environment (rStats) at the University of 
Massachusetts Medical School. This Unix -based en vironm ent is not accessible f rom 
outside of the medical school and only medical school s taff with IRB approval ar e 
assigned an acc ount i n this environment . We will program the system for a single entry 
with validation rules for validity, consistency, and n ormal range values at the tim e of 
entry and comprehensive edits through multivariable ed it approaches conducted a fter 
the data hav e been  submitted to the main data base. Edit queries will be resolved by 
clinic staff with corrections posted to the database throug h the REDCap system, wh ich 
enforces an audit trail for all changes.  
 
The main stud y database will be stored  on a secure serv er in the University of 
Massachusetts HIPAA -compliant data center with daily back -up. REDCap will be used 
within the rStats en vironm ent to protect any PHI/ PII data that are collected as part of the 
study. We will s trive to minimize collect ion of such data and RE DCap will be 
programmed to segregate that data from the main study data so that exports for 
analysis will be deidentifie d. 
 
Data will be exported fro m REDCap for import into the latest version of statistical 
software (e.g., SAS, SAS Institute, Cary, NC) for all analysis. All reports and analyses 
will be generated from these files using the latest version of SAS (currently S AS 9.3 ). 
Data files (and acco mpanying SAS programs) that are used for reports, presentat ions, 
or publication will  be archived as r equired past the end of the study.  The REDCap 
system will be programmed and maintained by study staff at the U Mass Medical Sc hool 
while data entry will be  performed by research study staff at the U Mass Medical Sc hool 
and at the U Pittsbu rgh Medical Schoo l.  
 
To the extent possible, data  from the laboratory assays will be conveyed electronically 
and uploaded directly into REDCap . Edit checks will be built i nto the upload process to 
identify any out -of-normal range values. Any edit queries will be forwarded  to the 
appropriate laboratory fo r resolution. If a direct upload is not possible, a REDCap data 
entry screen will be implemen ted fo r the laboratory data.  
 
4.3.  Data Analysis Plan  
4.3.1. Overview . Table 1 provides  a summary list of outcom e variables for e ach 
Specific Aim. Descriptive sta tistics will be calculated (means/SD or median/IQR) by 
treatment group. Because infants will be rep eatedly observed and me asured, initial 
analyses comparing outcomes between the tre atment groups (SVS vs SCC ) will be 
conduct ed using standard approaches assu ming a normal distribution (i.e., two -sample 
t-test) or using non -parametric alternatives if assump tion of a normal distri bution is not 
appropriate (i.e., Mann -Whitney U Test). We w ill use mixed effect mode ls to analyze the  
repeated measures over time. The se models will estimate the trajectory of outcomes 
over time within each treatment group as a ffecte d by condition and othe r factors of 
interest. The time metric for these models wil l be hrs since birth for Aims 1 and 2 for 
each measurement so that the traj ectories will relate to the same baseline 
  Page 13 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 measurement for all infants. Treatment group will b e cons idered as fixed effect in the 
models, with other factors considered to be either f ixed or random effects, d epending on 
the n ature of the factor: opioid only vs opioid+other; gender, delivery mode (vaginal or 
caesarean -section); delivery anesthetics ( none v s anesthetics). Compreh ensive 
histories from medical record and questionnaire will  allow us to examine the influence of 
additional variables  
 
   4.3.2 Specif ic Aim 1 : We will use mixed effects models as described above to 
examine whether infants trea ted wi th SVS compared to SCC have: 1) Lower daily 
average and maximum NAS scores; 2) Les s morphine requirement (p rimary 
pharmacolo gical treatment for managing NAS at both sites; cumulative dose normalized 
for body weight); 3) Enhanced velocity of weight ga in throughout hospitalization ; and 4) 
Shorter hospitalization length of stay. A model wi ll be fit for each outcom e using 
Nagelkerk e’s R2 to determine the model wit h the best fit using the ratio of the -2 log 
likelihoods for the model with covariates compar ed to the intercept -only mode l. Factors 
of interest will be included in the model as app ropriate and interactions  with treatment 
group will be tested as well. The interactions will indicate whether the treatment effect is 
the same across subgroups. Additio nal an alyses to identify grou ps of infants who do 
particularly well (or poorly) with SVS  will be conducted using latent class tech niques, 
such as cluster analysis (for continuous variables) or latent class analysis (for discrete 
variables). The factors of intere st will include: drug e xposure (e.g., prescribed 
maintenance therapy, prescription  drugs and illicit substa nce; with or with out poly -drug 
use), demographic d ata (gender, race, gestational age, birth weight, birth head 
circumference, delivery mode, an esthes ia at delivery), and fe ed type (formula or breast 
milk) . 
 
 Movement : Actigraphy (movement activity frequenc y) will be compar ed across days 
and between Groups  using similar mixed effects models as above . The outcomes of 
interest are actigraphy  through out ho spitalization to determ ine if SVS reduces 
movement and increases quiescence  episod es over time (12 and 24 h our assessments)  
compared to SCC .  
 
    4.3.3. Specific Aim 2 : Study design allows systematic quantification of condition 
effects on breathing (IBI v ariance and respiratory  rate), cardiac rhythm (R -R variance 
and heart rate), movem ent activity  (frequency a nd duration), blo od oxygenati on 
(durations<85% ), and skin temperature.  Histogram of frequency -bands of cardio, 
respiratory and movement inciden ts will be determined.  As wit h Aim 1, mixed effects 
models will be used to examine if SV S, within infants and bet ween SVS and SCC 
infants : 1) Decreases  irritabilit y and sleep disruption/fragmentation indexed by 
movement frequency and duration; 2) Improves cardio -respiratory control: r educes  
bradycardia/br adypnea, tachycardia/tachypnea and inc reases  incidents of 
eucar dia/eupnea; and 3 ) Reduces  other NAS symptoms : e.g., temperature; 
oxygenation . Additional c omputational signal analysis. We have developed nove l 
statistical point process algorithms  that measure cardio -respiratory dynamics and 
move ment over continuous time  domains .[67, 68]The variable characteristics of 
respiratory (IBI)  and cardiac (RR) signals are integr ated w ith the dynamic ch aract eristics 
of these signals to  provide instantaneous, moving estimate of mean, varianc e and other 
  Page 14 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 dynam ic measures (e.g., spectrum, pole s, frequency) .[68] These measures will be used 
to exami ne temporal dynamics of  respiratory and heart rate rhythm, and explore 
correspondi ng physiological relation ships with moveme nt over time ; e.g., Do  IBI 
change s that reflect caudal brainstem function precede cortical behaviors such as 
arousal (e.g., mo vement )? Time series of movem ent periods will be analyzed using 
Wavelet derived SAP thro ughout stimulation ON and  OFF to evaluate temporal 
dynamics including: 1) R esponse time for improvement in rhythm relative to the onset of 
stimulation; 2) Whether there  is loss of efficacy over tim e (during each 30 min stimulus 
period as well as from one p eriod to the next); 3) Wh ether improvement  in rhythm 
persists f ollowing off set of stimulation.   
 
  4.3.4.  Specific Aim 3. One -Year Outcomes’ Assessment . We will use a 
genera l linear model approach  to analyze outcomes over one year, using the same 
model bu ilding strategies describ ed above. Some ou tcomes, such as the Bayley -III 
scales, are collected at multiple follow -up visits so we will use mixed effects models to 
estim ate treatment effect over tim e and to adjust for other covariates. Impairment is 
determi ned based on a fairly ext ensive neurobehav ioral test battery but the compon ent 
test scores are highly correlated. To control for error that results from this correlatio n, 
we will reduce the number of tests by evaluating the domain or summary scores from 
the various instruments and  use the approach  of Ingraham and Aiken[69] to determine 
how many deviant scores are required to identify a child as impaired. This approach 
calculates th e criteria for abnormality wh en employing batteries of multiple tests by 
generating prob ability curves for exceed ing cut -off crite ria by chance given certain 
criteria (e.g., an expectation that one group will show a decrement). This type of 
analysis will a llow u s to look at rate of im pairment in young children with opioid 
exposure and assess whether SVS compared to S SC reduces likeli hood of impairment.  
 
5 QUALITY ASSURANCE  
 
5.1.  Procedures in Pla ce to Ensure the Validity and Integrity of the Data  
Quality As surance of data entry and da ta m anagem ent consists of a set of proactive 
tools that are implemented to increase the qual ity of  the data processing components 
including: (1) F orm design to avoid structural missingness, orphan questions, and as 
many “write -in” responses as possible; (2 ) Training  of the data entry operators on the 
study forms so that they are familiar with the  required responses; (3) D esign of the data 
entry screens to look as much like th e paper forms as possible; (4) S pecifications of the 
data fields to reflect the nat ure of the  data to be entered; (5) S pecification of the edit 
parameters and checking  algorit hms so th at every field is verified as c ompletely as 
possible; and (6) V alidation of the database system to certify that data entered in to the 
data entry screens ar e accurate ly recorded in the databases.  
 
 In other areas, quality assurance will be implemen ted in  a variety of ways: (1) 
Training of the research staff on data colle ction techniques with periodic retraining; and 
(2) Immediate r eview of data collection to be sure th at data collection forms are fully 
complete.  All staff will be trained on  the pro tocol and  issued certification numbers for 
the study. Staff will have to b e certified in an area (such as data entry and patient 
  Page 15 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 randomi zation) before the study sys tems  will allow them to perform those tasks. All 
study systems will require a dual l evel log in proced ure for each task.   
 
5.2.  Procedures to Guarantee the Accuracy and Completeness of the Data, 
During Data Collection, Entry, T ransmission, and Analysis  
 For quality  control measures, regular analyses will report on: (1) Number of missing 
data ite ms; (2) Number and type of forms that are failing edit; and (3) Distributi on of 
data to look for outliers. A Quality Control report will  be generated at the same ti me a s 
the DSMB report for review by study leadership and by the DSMB.  In addition to  the 
quality assu rance/quality control plans for data entry described above, we wi ll select a 
10% sample of patients each quarter to review sele ct (high -risk) data for veri fication 
against source documents, including patient characteristics and laboratory assay 
results. Any item discrepancies of greater than 2% will be discussed with th e site data 
coordinator  and retraining/additional observation instituted if required.   
 
 Only resea rch team members will have access to subject identifying information, 
which will b e stored electronically only in the participant tracking database in the U  
Mass Medical School regulated environment. Each patient will be identified with a study 
ID nu mber w hich will be used on all data collection forms. Only the participant track ing 
database will  have the link between the study ID number and the PII of the pat ient. 
 
5.3  Monitoring Missing Data  
Reports on missing data wi ll be reviewed by the DSMB, including missing forms and 
missing data items. In addition, for data that are missi ng, we w ill consi der appropriate 
imputation procedures, such as model -based multip le imputation , for study analyses . To 
identify spurious data, we will implement edit check s at data entry for values that are out 
of normal range, inconsistent values, and im proper d ata entry  so that most problems will 
be detected during data entry. Additi onal edit checks will be implemented to run when 
the data are submitted to the main study database. These will include edits across visits 
and across forms, so that large cha nges bet ween visi ts and inconsistent responses 
between case report forms will gene rate an edit query. Edit queries will be forwarded to 
the appr opriate clinical site coordi nator for resolution through changes done through 
REDCap. The implementation of REDC ap at Un iversity of Massachusetts Medical 
School has the audit trail fully impleme nted so that any changes to the original 
submitted data are re corded and documented.  
 
6  REGUL ATORY ISSUES  
 
6.1.  Reporting of Serious Adverse Events (SAE) and Suspected Adve rse 
Reac tions (SA R) 
With regard to serious adverse events and suspected adverse re actions, both expected 
and unexpected and regardless of whethe r the SAE/SARs are considere d related to the 
study intervention and/or th e in utero  drug exposure and subsequent  NAS, they will b e 
followed in a rigorous review process through the entire trial period. Clinical 
performance sites will be instructed to repor t all fatal events, unantici pated prob lems 
and other serious adverse events and suspected adverse reactions to t he DSMB and 
  Page 16 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 IRB b y secure email within 24 hours of first knowledge of the event. All SAES must be 
reported to NIDA within 72 hours. Additionally , all current study data for  that part icular 
subject will be entered to allow for timely review by the Externa l Medical Safety Mo nitor 
(EMSM ).  
 
The EMSM will closely monitor the incidence rates of all adverse events reported, 
whether serious or not, throu ghout the study, and will al ert the DS MB if a trend is 
observed. A significant increase in the rate of adverse e vents in  the SVS  treatment 
group would be  cause for concern for the safety of participants in the study. Information 
on adverse events will be p resented in s everal ways: (1 ) Listings  of serious adverse 
events with accompanying narrative summary by the Safe ty Offic er wit h input from the 
Study PI; (2) S ummaries of adverse events by body system and type of event. This 
information will be presented by  blinded  treatment group (i. e., SVS an d SCC ) to the 
DSMB for each group. In addition, the Safety Officer will be  given t reatment information 
in a blinded  fashion, although he/she can request to be unblinded in cases where that 
knowledge could be critical.  
 
Serious adverse events shou ld not be reported for hospitalization or prolonged 
hospitalization in the following  scenari os: for a  diagnostic or elective surgical procedure 
related to a preexisting condition; to allow for an efficacy measure for the study; or, for a 
planned surgical p rocedure t hat was not the result of a condition worsening due to 
participation in th e study.  
 
A summa ry of all AEs and SAEs, a summary of all reports, and a coded list of all 
subjects who were terminated from the study due to st udy-related adverse events, will 
be in cluded in reports submitted by the DSMB to the IRBs. An annual report will  be 
subm itted to the IRBs at all particip ating sites.   NIH NIDA will also receive all reports.  
 
6.1.1. Definitions . 
http://www.accessdata.fda.gov/scripts/cdrh/c fdocs/cf cfr/CFRSe arch.cfm?fr=56.102    
The clinical site investigator, on the basis of his or her clinical judgment and the 
following definition s, determines the relationsh ip of the adverse event to the protocol 
intervention as one of the following:  
• Def initely:  Any adve rse reaction and those a dverse events that cannot be 
reasonably explained by an alternative explanation, e.g., concomitant drug (s), 
concomitant disease(s).  The relationship in time is very suggestive, e.g., 
improvement coinciding with disc ontinuat ion and r ecurrence on reinstituti on.  
• Probably: An AE that might be due to the use of the study intervention . The 
relationship in time  is suggestive, e.g., improv emen t coin ciding with discontinuation. 
An alternative explanation is less likely, e. g., conc omitant d rug(s), concomitant 
disease(s); and, other causes have been eliminated or are unlikely.  
• Possibly: An AE that might be due to  the use of the study interv ention. An 
alternative explanation, e.g., concomitant drug(s), concomitant disease(s ) is 
inconclusive . The relationship in ti me is reasonable; therefore, the causal 
relationship cannot be excluded and while other potential cause s may or may not 
exist, a ca usal relationship to the study drug does not appear probable.  
  Page 17 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518  
 6.1.2. Adverse Even t Follow -Up. Subjects with adverse events  (both serious 
and non -serious) will be followed as clinical ly indicated and no less often than specifi ed 
by this protocol for stan dard follow-up of subjects enrolled in the study. At those visits, 
updated informati on on th e adverse  event will be collected  and entered into the 
REDCap data capture system until the adverse event is completely resolved.  
 
6.2 Reporting of IRB Actions to N IDA 
 All actions of the UMMS or U Pitt IRBs related to the conduct of this study wil l be 
reported to the NIDA Project Officer  immediately. Any additional follow -up will be 
discussed at that time.  
 
6.3 Report ing of Changes or Amendments to the Protocol  
This study wi ll be conducted in compliance with the protocol approved by the 
Institutio nal Revi ew Board and according to Goo d Clinical Practice standards. No 
deviation from the protocol will be implemented without the prior review and approval of 
the IRB exce pt where i t may be necessary to eliminate an immediate hazard to a 
research subject.  In such  case, th e deviation will be repo rted to the IRB as soon as 
possible.  Any change or amendment to the protocol must have prior approval f rom 
NIDA PO.  
 
6.4 Trial Stop ping  Rules 
There will be no formal statistical stopping boundaries proposed for this  study, although 
the DSMB can request suc h boundaries be determined at any time during the study for 
both safety and efficacy (including futilit y). However, an apparent, co nsistent a nd 
persistent evidence of net harm that tends to overwhelm any benefit may  allow f or 
premat ure termination of the s tudy. Continuing enrollment into each cohort will be 
determined in an ongoing basis and at periodic int ervals. The DSMB will receiv e a 
report  on all reported AEs and SAEs as well as the proportion of subjects with a ny 
speci fic event  of interest. The findin g of any unexpected serious adverse event 
considered to be related to study intervention  in 2 of 6 pati ents will lead to review and  
suspensio n of recruitment and review of the complete data by the External Medical 
Safety Mo nitor (EM SM).  
 
Following the EMS M’s review, the safety report (and any comments from the 
EMSM) will be sent to the DSMB. The DSMB will make the final recommendatio n for 
early termination versus continuation of the study after reviewing the availab le data.  The 
decision will be guided by s afety. In addition to the planned evaluations, the EMSM and 
DSMB will receive quarterly safety summary reports of enrollment, basel ine 
demogr aphics, withdrawals from treatment and all AEs and SAEs with information o n 
relati on to stu dy treatment.  
 
  Page 18 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 6.5 Discl osure of any conflict of interest  (COI)  in the DSM P  
Conflict of Interest .  The PI (Salisbury) is a co -inventor on a patent for use  of the 
uniquely constructed mattress that delivers the SVS. There is an approved mi tigation  
plan in place at UMass due to a potential financial conflict of interest : 1) Dr. Salisbury 
will not be involved in enrolling or consent ing clinical study participa nts; 2) Th e consent 
will convey potential financial interest in the clinical study; 3) Data analysis will be 
subject to a bia nnual Quality Assurance review by a suitable member of the UMMS 
human research protection program not o therwise associated with the  Clinical Study. 
We will obtain required approvals for Dr. Salisbury to conduct stud ies at U Pitt as p er the 
Conflict of Inter est Committee requirements at UPitt.    
 
7 TRIAL SAFETY  
 
7.1   Potential Risks and Benefits for P articip ants 
7.1.1. Potential Risks  
 
There are  no known risks of SVS mattress to be used in this study. While it may be 
difficul t to disc ern whether changes in w ithdrawal symptoms are due to the intervention 
or to related system dysregulation of NAS, the protocol may be discontinued at any t ime 
if the  investigators or the infant’s doctor suspects there are any adverse effec ts on 
breathing, heart rate, temperature,  oxygenation, movement -irritability or any other 
function.  
 
 The additional physiological recording me asures to be used in this st udy are 
standard devices used on infants (e.g., surface sensors to record muscle act ivity, h eart 
leads, respiratory plethysmo graph belts placed around the surface of the infant’s rib 
cage and abdomen to record movement of respir atory muscles etc); they pos e minimal 
risk of skin irritation from the adhesive/foam bracelets used to hold the sensors in place.  
Potential risk of infec tion is minimized by using primarily disposable sensors, and 
cleaning with sterilizing wipes any non -disposable sensors before and after each  use. 
There is the potential risk of breach of confidentiality, but this i s minimi zed by us ing 
alpha -numeric study code to identify subject data; furthermore all research related 
computers username and password protect ed. Names will not be used i n any repo rts or 
publications of this study.   
 
7.1.2. Potential Benefits  
 
There are no known  immediat e direct benefits to the  subjects or others. Although it is 
hoped that infants assigned to the SVS group may benefit from SVS i f NAS symptoms 
are reduced a nd 1-year outcomes are improved, this will not be evident until completion 
of the st udy.  
 
7.2  Colle ction and R eporting of A Es and SAEs  
 
 Adverse events, as defined in the protocol, will be collected from the date and 
time of r andomization to the dat e and time of h ospital discharge as discussed above in 
  Page 19 
Salisbury R01 DA04 2074  DSM_  Protocol a nd SAP  v051518 Section 6.1 . All adverse events wi ll be co ded using  MedDRA and will be repo rted to the 
DSMB in tabular form organized by patient, showing the adverse event  with the 
preferred ter m grouped within system orga n class as  well as relatedness to the 
treatment. Table s will show the treatment -emer gent adv erse even ts, i.e., adverse 
events  that occurred after randomization or worsened after randomization. These tables 
will be reviewed at ev ery DSMB meeting (and more f requently if requested).   
 
7.3 Management of SAEs or Other Study R isks 
 
 In the even t of a s erious ad verse event, from diseas e or drug, the clinical 
presentation will be immediately reviewed by the study leadership. Management o f the 
SAE will be chosen on the basis of the collective clinical decision -making of the 
investigators and the ot her phys icians in volved in the patient’s care.  
 
Any fatal events, unanticipated problems and other serious adverse events and 
suspected adverse  reactions will be reported to the DSM B and IRB s by secure email 
within 24 hours of first knowledge of the event . Additi onally, a ll current study data 
for that particular subject will be entered to allow for timely review by the External Safety 
Monitor.  
 
SAEs will be reported to the  DSM B and IRBs as indicated above. The DSMB 
also will review tabulated summaries of SAE in t he same f ormat as AEs as well as 
listings of the details for each SAE, grouped within infants (for those infants with more 
than one). A narrative summary of the SAE  and treatment for it will be included.  
 
An annual report will be submitted to the I RBs at a ll partic ipating sites. A 
summary  of all adverse events (AEs) and serious adverse events (SAEs), a summary of 
all reports, and a coded l ist of all subjects who were  terminate d from the study due to 
study -related adverse events, will be included in reports submitted  by the DMSB to the 
IRBs . The funding institute, NIH OBA and FDA will also receive all reports.  
  
 
 